"Serious" and "severe" adverse drug reactions need defining

Comment

Christian Frankenfeld. BMJ. 2004.

. 2004 Sep 4;329(7465):573.

doi: 10.1136/bmj.329.7465.573.

No abstract available

Comment in

Seriousness of adverse events: medical judgment is important.
Borja J, Donado E, Souto M. Borja J, et al. BMJ. 2004 Dec 11;329(7479):1405. doi: 10.1136/bmj.329.7479.1405. BMJ. 2004. PMID: 15591583 Free PMC article. No abstract available.

Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study.
Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Schlagenhauf P, et al. BMJ. 2003 Nov 8;327(7423):1078. doi: 10.1136/bmj.327.7423.1078. BMJ. 2003. PMID: 14604928 Free PMC article. Clinical Trial.
Preventing malaria in UK travellers.
Zuckerman JN. Zuckerman JN. BMJ. 2004 Aug 7;329(7461):305-6. doi: 10.1136/bmj.329.7461.305. BMJ. 2004. PMID: 15297324 Free PMC article. No abstract available.

1. Zuckerman JN. Preventing malaria in UK travellers. BMJ 2004;329: 305-6. (7 August.) - PMC - PubMed
1. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003;327: 1078. - PMC - PubMed
1. Council for International Organisations of Medical Sciences. International reporting of adverse drug reactions. CIOMS working group report. Geneva: World Health Organisation, 1987.
1. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001;33: 1015-21. - PubMed
1. Lariam (mefloquine hydrochloride) medication guide. Nutley: Hoffmann La Roche USA, August 2003. www.fda.gov/medwatch/SAFETY/2003/LariamMedGuide.pdf. (accessed 21 Aug 2004).